Is Janux Therapeutics, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for Janux Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is considered overvalued given its current metrics, particularly with a Price to Book Value of 1.54, an EV to EBIT of -4.84, and an EV to EBITDA of -4.93, which reflect negative earnings performance.
In comparison to its peer Avidity Biosciences, Inc., which has a P/E ratio of -13.5642 and an EV to EBITDA of -9.6438, Janux appears to be in a weaker position. The company's returns have also lagged significantly behind the S&P 500, with a year-to-date return of -54.43% compared to the index's 12.22%, reinforcing the perception of overvaluation.